# <sup>1</sup> Utility of family history in disease prediction in the era of polygenic<br><sup>2</sup> scores



# $\frac{1}{2}$



12  $\overline{1}$ 



21 **Polygenic scores usher** i 21 Polygenic scores usher in a new era of risk prediction

 $\overline{a}$ 

1 Genome-wide association study (GWAS) results are increasingly used to estimate a<br>2 PGS for individuals by summing over a person's disease-risk alleles weighted by their impact 3 on disease risk. Studies in CAD shows that individuals with the highest 5% of genome-wide  $4$  PGSs for CAD have more than a threefold higher risk of CAD than the rest of the population<sup>10</sup>.  $5<sub>5</sub>$  This is similar to the increased CAD risk conferred by monogenic mutations, such as those 6 causing familial hypercholesterolemia (LDLR, APOB, and PCSK9). However, 20 times as many 7 people fall into the PGS high-risk category relative to those who carry a monogenic mutation<sup>10</sup>, 8 suggesting that more cardiovascular events could be prevented by selecting individuals based 9 on high PGS in comparison to those with Mendelian mutations. The use of PGS for screening 10 earlier in life is likely preferred to models based on clinical risk factors such as high lipid levels, 11 because individuals falling in the top tail of the PGS distribution typically have earlier disease 12 onset and preventive approaches can be applied prior to development of clinical risk factors. A 13 previous study demonstrated that individuals in the top 2.5% of the PGS distribution were  $14$  diagnosed with CAD 4.4 years earlier than individuals with average PGS, and for T2D 13.4 years 14 diagnosed with CAD 4.4 years earlier than individuals with average PCS, and for T2D 13.4 years earlier than  $\frac{1}{2}$ . 15 earlier<sup>11</sup>.<br>16 **Incorporating family history in an era of polygenic scores** 

17 Several studies have evaluated the inclusion of self-reported family history alongside 18 genetics in risk-prediction models for complex diseases such as Crohn's<sup>12</sup>, CAD<sup>13,14</sup>, breast genetical cancer<sup>15</sup>, and prostate cancer<sup>16,17</sup>. We previously evaluated the use of family history informed 20 genetic risk score (FHiGRS)<sup>18</sup>, and a recently developed method, PRS-FH, combines PGS and 21 family history to improve the accuracy of PGS, particularly in diverse populations<sup>19</sup>. The use of 22 six conventional risk factors for CAD, including family history of heart disease, was shown to

 $22$  six conventional risk factors for  $\mu$  including family history of heart disease, was shown to

 $\frac{4}{3}$ 



20 LDpred and then divided the sample into 20 ventiles, each containing 5% of the sample, to 21 assess the prevalence of disease across the PGS distribution. To assess the impact of family

22 history, we collected self-reported family history reports surveys at the time of study

22 history, we collected self-reported family history reports surveys at the time of study

 $\overline{a}$ 







Figure 1: CAD prevalence across PGS quantiles, stratified by family history of myocardial infarction in HUNT. Prevalence<br>of coronary artery disease per polygenic score ventile in the entire population of HUNT, stratified b 5 of coronary artery disease per polygenic score ventile in the entire population of HONT, stratified by sen-reported family<br>6 history of myocardial infarction (MI). 6 history of myocardial infarction (MI).

 $\overline{a}$ 



It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.06.25.21259158;](https://doi.org/10.1101/2021.06.25.21259158) this version posted June 28, 2021. The copyright holder for this preprint

### 1 Age matters with respect to family history in risk prediction models



s incidence.<br>9 The 9 The average age of first MI in HUNT was 70.5 years (95% CI 70.3,70.9). A positive family 10 history for MI was significantly predicted by older age at enrollment (2-sided p-value < 2 x 10  $^{\,308}$ ). HUNT2 participants were asked if they have a family member who had an MI before the <sup>30</sup>°). HUNT2 participants were asked if they have a family member who had an MI before the<br>12 age of 60: sixteen percent of participants between 19-40 years of age reported "yes" versus 13 52% of participants over 40 years of age. Similarly, the median enrollment age of persons 14 reporting no affected first degree relative was significantly lower than the age of persons 15 reporting positive family history (35.5 versus 50.7 years, WRST 1-sided p-value < 2.2 x 10<sup>308</sup>, 16 Figure 2). In HUNT2, the survey metric specified the relationship type experiencing a MI before 17 60 years of age. Individuals that reported a sibling or child with the disease were slightly older 18 than individuals who reported affected parents ( $48.7$  versus  $48.2$  years, WRST 1-sided p-19 than individuals who reported after parents (48.7 versus 48.7 versus 48.7 versus 48.2 years, WRST 1-sided p 19 value=7.9x10<sup>-11</sup>).<br>20

21

22







 $\frac{4}{5}$ 5 This finding is not surprising for common, complex diseases—as someone ages, their<br>6 relatives also age and are at a higher risk of disease. However, this finding encourages careful 7 collection of the age at which an individual self-reports family history of disease. Presently, the 8 accuracy of self-reported family history is imperfect, with some studies indicating specificity 9 accuracy ranging from  $75-98\%$  for common conditions such as diabetes and obesity<sup>27</sup>. We found age at 10 self-report of family history was an important variable to control for when using family history 11 in prediction models (Supplementary Figure 4). Within the HUNT longitudinal study, we 12 identified instances where more recent family history data were used to correct or update past 13 family history variables from questionnaires, which de-coupled family history from the

 $\frac{1}{2}$  family history variables from  $\frac{1}{2}$  family history from the coupled family hist



 $\overline{9}$ 

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.06.25.21259158;](https://doi.org/10.1101/2021.06.25.21259158) this version posted June 28, 2021. The copyright holder for this preprint



 $12$ <br> $345$ 2 Figure 3 Family history and PGS as predictors of CAD across biobank enrollment ages. Each model is adjusted for principal<br>2 Components 1-4 from genetic data, participation age, participation age squared, birthyear, sex, 3 components 1-4 from genetic data, participation age, participation age squared, birthyear, sex, and genotyping batch Odds<br>4 ratio for PGS is for continuous PGS (yellow) and for FH is for positive family history (green) w 4 ratio for PGS is for continuous PGS (yellow) and for FH is for positive family history (green) within the enfollment age bin and<br>5 for.<br>6 5 for.<br>6

6 7 At first glance, family history is an ideal predictive indicator for CAD, since it is<br>8 inexpensive and easy to obtain, however, the paucity of familial disease events for young 9 individuals (Figure 2) suggests family history may be a less effective predictive tool than PGS 10 for early intervention. Before 40 years of age, we expect that family history might help capture 11 individuals at risk due to familial monogenic mutations causing early onset disease in parents, 12 but is probably not as helpful in cases of polygenic genetic variation causing later disease onset 13 (Figure 3). By the time a sibling is old enough to become affected, the benefit of family history 14 as a disease predictor is less useful as the time frame for preventive interventions for the 15 individual may have mostly passed. A tool that has its greatest predictive effect after the 16 average age of disease onset is likely less effective. This finding may prove to limit the utility of 16 average age of disease onset is likely less effective. This finding may prove to limit the utility of  $\alpha$   $\mathbf{1}$ 1 family history to predict laterature in since diseases of the conset of the siblings of the siblings or siblings or  $\frac{1}{2}$ 

 $\frac{1}{3}$  A 3 As more effective preventive strategies are introduced and rates of cardiovascular<br>4 disease decrease in the population, we expect rates of positive family history to decrease in 5 frequency. While this will be a welcome outcome of precision medicine, it does have 6 framifications for predictors such as family history which are a function of disease incidence. 7 This has been observed for individuals with familial hypercholesterolemia, in whom high-8 intensity lipid-lowering therapies have dramatically decreased the risk of MI<sup>28</sup>. As of 2013, g  $-$  27.8% of the general adult (>40 years of age) population in the United States report using 9 20 20 years of the general advanced and the general advanced by the general advanced Statins, and 52.7% of patients with ASCVD use statins  $^{29}$ . Recent research suggests highstatins, and 52.7% of patients with ASCVD use statins<sup>29</sup>. Recent research suggests high-<br>-<br>11 intensity statin usage could prevent 51-71% of premature ASCVD events (1.4 million eve 11 intensity statin usage could prevent 51-71% of premature ASCVD events (1.4 million events in<br>12 the US) when patients aged 30-39 are treated for 30 years<sup>30</sup>. Using genetically inferred kinship 13 in the subset of HUNT for which we have statin information (HUNT3,  $N=14.055$ ), of the 2.595 14 first degree relatives of cases, 26.8% take statins compared to 16.8% of individuals not related 15 to a case (Chi-square p-value=3.6x10<sup>-58</sup>). A person with a high risk of ASCVD may have relatives 16 on statins, which prevents disease progression, and therefore report a negative family history. 17 For this reason, the utility of family history as a predictor across the lifespan will need detailed 18 evaluation and may change for different generations.

19 Family history and PGS trends replicate for Type 2 Diabetes

20 We evaluated the same models for T2D, another complex disease with environmental 21 and genetic risk factors and with well-powered GWAS available for the PGS. Similar to CAD, 22 we observed an overlap of the family history strata with the top  $\zeta\%$  of PGS<sub>T2D</sub> individuals with 22 we observed an overlap of the family history strata with the top 5% of PGST2D individuals with

 $\overline{1}$ 





2<br>3<br>4 3 Figure 4 T2D prevalence across PGS quantiles, stratified by family history of diabetes in HONT. The prevalence of Type 2<br>4 diabetes per polygenic score ventile in the entire population of HUNT and stratified by self-repo 4 diabetes per polygenic score ventile in the entire population of HUNT and stratified by self-reported family history of diabetes.

Similar to the observations for CAD, the Pearson correlation between age of enrollment participants report a positive family history of T2D, versus 35% of participants greater than  $\mu$ o years of age. Both PGS and family history (when modeled together) are significant across the lifespan for T2D (Figure 5). The odds ratio estimated for family history of T2D had a U-shaped curve with higher odds of disease indicated by family history on both tails of enrollment age (Figure  $\varsigma$ ), again similar to the pattern observed for CAD association with family history of MI. (Figure 5), again similar to the pattern observed for CAD association with family history of MI.



Figure 5 Family history and PGS as predictors of T2D across biobank emolinent ages in HUNT. Each model is adjusted for<br>principal components 1-4 from genetic data, participation age, participation age squared, birthyear, se principal components 1-4 from genetic data, participation age, participation age squared, birthyear, sex, and genotyping batch.

### Family history and PGS trends replicate in the UK Biobank

When we assessed the relationships between family history, polygenic score and disease<br>prevalence in the UK Biobank, an increased disease prevalence was observed in individuals in

prevalence in the UK Biobank, an increased disease prevalence was observed in individuals in

the top tail of the PGS distribution with a positive self-reported family history for both CAD family history for heart disease and younger enrollment ages was also observed (Supplementary Figure 8). Using the covariates from the model selection from HUNT, we observed similar odds ratios for clinical predictors in UK Biobank as in HUNT (Supplementary Table 2,4). In the UK Biobank, a model with predictors for both family history and PGS and their interaction were significant terms for CAD, but the interaction term between PGS and family history was not significant for T2D (Supplementary Table  $\zeta$ ).

# family history was not significant for T2D (Supplementary Table 5). Improving family history and polygenic scores to advance prediction of CAD

Current American Heart Association guidelines for lipid-lowering (i.e., statin, ezetimibe CVD events, LDL-C levels, 10-year ASCVD risk estimated by PCE, diabetes status, age, and coronary artery calcium score<sup>23</sup>. Family history is considered a risk enhancing factor, however, we advocate for formal inclusion of both family history and PGS to risk estimation models given that both variables are significant and independent predictors of CAD in HUNT and UK Biobank. Currently PGSs are limited by trans-ethnic portability<sup>31,32</sup>, sensitivity to population stratification<sup>33</sup>, and miscalibration<sup>34</sup> among other considerations. Future iterations of PGSs may integrate genetic risk for clinical risk factors such as genetic prediction of LDL cholesterol or body mass index or other multi-trait risk models that improve prediction. The addition of an easily ascertained predictor such as family history suggests we should incorporate this variable as we continue to evaluate the use of other biomarker PGSs (as in Sinnott-Armstrong et  $a^{\beta 5}$ ) as we continue to evaluate the use of other biomarker PGSs (as in Sinnott-Armstrong *et al<sup>ss</sup>)*<br>and clinical risk factors to predict disease (as in Inouye *et al<sup>20</sup>),* particularly early in life. and clinical risk factors to predict disease (as in Inouye *et ɑl<sup>20</sup>)*, particularly early in life.<br>And clinical risk factors to predict disease (as in Inouye *et ɑl<sup>20</sup>),* particularly early in life.

Family history must be consistently recorded in the electronic health record to be the presence or absence of family history is less informative than more precise family history records such as: age at time of family history report, the number of affected relatives, relationship to relatives with disease, severity of disease in the family member, or the age of disease onset/diagnosis in these relatives. Differentiating between first-degree relative (mother, father, sibling) and second degree relative (grandparent, aunt, uncle) will yield specificity as to the degree of shared genetic liability. Even more useful is a grid of diseases and relationships to allow for higher resolution family history variables. As providers move towards electronic surveys at intake of clinical appointments, logic allowing for more detailed questions about family members with specific diseases listed on the grid should be implemented. The age at time of reporting family history should be recorded and regular updates to both the family history information (coupled with age at time of report) will improve prediction based family information (coupled with age at time of report) will improve prediction based<br>on family history. on family history.<br>These richer predictive features are rarely systematically collected in biobank surveys,

clinic visits, or the electronic health record, and we contend that this detailed documentation will enable greater predictive accuracy and contribute to earlier intervention with preventive therapies. We observed similar levels of utility and independence of family history and PGS association with  $T_2D$  as with CAD. In the absence of quantitative risk prediction algorithms for T<sub>2</sub>D (such as the PCE for CAD), our work suggests the potential utility of family history and PGS in addition to clinical measurements such as HbA1C. Additional studies should be performed in traits with Mendelian inheritance patterns (e.g., breast cancer) and early onset  $p = 1$  traits with Mendelian inheritance patterns (e.g., breast cancer) and early onsetting

discreption of the utility of the utility of the utility of  $\mathcal{C}$  and  $\mathcal{C}$  are spectrum of  $\mathcal{C}$  of  $\mathcal{C}$  . prevalence, heritability and genetic architecture.<br>Conclusion

**Conclusion**<br>In two electronic health record-linked biobanks, HUNT and UK Biobank, we evaluated the association of family history and PGS with two different diseases: CAD and T2D. We confirm that family history and PGS are both significant and mostly independent predictors of disease by evaluating CAD and T2D prevalence. Given the significant but weak interaction between family history and PGS, we note that family history is not simply a proxy for PGS, but likely represents lifestyle and social determinants of health, and is therefore, an important component of risk prediction in addition to PGS. We demonstrate increasing rates of positive family history with increasing age at report of family history. We also highlight that positive family history of MI is less common at younger ages, when relatives are also young, but family history also has the highest impact on odds of CAD in this age group. We suggest advancing electronic health record-linked biobank infrastructure to enable meaningful integration of detailed family history and PGS to improve upon current ASCVD risk estimation with PCE detailed family history and PGS to improve upon current ASCVD risk estimation with PCE<br>leading to prevention of disease. leading to prevention of disease.

### Acknowledgements

We thank all research participants in the HUNT study and the UK Biobank for their<br>dedication towards improving human health. We thank Bethany Klunder for project management. This research has been conducted using the UK Biobank Resource under application number  $24460$ . The HUNT-MI study, which comprises the genetic investigations of the HUNT Study, is a collaboration between investigators from the HUNT study and University of Michigan Medical School and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology (NTNU) and Central Norway Regional Health Authority. The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public

### URLs

## https://githob.com/bnwonord/FFireR\_score.<br>Conflict of Interest Conflict of Interest

C.J.W.'s spouse works for Regenerations for Regenerations in the Regeneration Pharmaceuticals. In the Regeneron Pharmaceuticals. In the Regeneration of the Regeneration of the Regeneration of the Regeneration of the Regene

# Pharmaceuticals, Inc. Funding

Funding for this study was provided by the National Institutes of Health to C.J.W. (Ro1<br>HL127564, R35 HL135824) and M.B. (Uo1 DK062370, Ro1 HG009976). B.N.W. was funded by<br>NSF Graduate Research Fellowship (DGE 1256260) and Hullary of the USS of the Howship (DGE 1256260) and NIH Training Program in Genomic<br>Science (T32 HG000040). N.J.D. was funded by a Foundation for Anesthesia Education and Science (T32 HG000040). N.J.D. was funded by a Foundation for Anesthesia Education and<br>Research (FAER) Mentored Research Training Grant. W.Z. was supported by the National Research (FAER) Mentored Research Training Grant. W.Z. was supported by the National Research (FAER) Mentored Research Training Grant. W.Z. was supported by the National

 $H_3$ 2 $H$ Go104 $64$ .

## <del>ے</del><br>Author Contrib Author Contributions

B.N.W. and C.J.W. designed the study. B.N.W. performed most of the primary analyses, with<br>assistance from I.S. B.N.W. wrote the manuscript and I.S., C.J.W., and W.E.H. revised. All other<br>authors contributed to study implem authors contributed to the study implementation. authors contributed to study implementation.<br>
authors

## Tables





An indicator variable was created for the various high risk definitions above. The model controlled for batch, participation age, participation age squared, birth year, principal components 1-4 from genetic data, and sex.

### Table 2 Full model estimates for CAD in HUNT



Adjusted for principal components 1-4 from genetic data and genotyping batch (HUNT)

Table 3 Model comparisons for CAD in HUNT



Comparison of models in HUNT with family history (FH) and polygenic score (PGS) using ANOVA. The base model is sex, birthyear, participant age, and participant age squared, and first four principal components from genetic data

## Supplementary Methods

### Trøndelag Health Study

Iag county, Norway, since 1984<sup>36</sup>. Participation in the HUNT Study is based on informe<br>t, and the study has been approved by the Data Inspectorate and the Regional Ethics<br>ttee for Medical Research in Norway. Of the >120, Trøndelag county, Norway, since 1984<sup>39</sup>. Participation in the HUNT Study is based on informed<br>consent, and the study has been approved by the Data Inspectorate and the Regional Ethics<br>Committee for Medical Research in Nor committee for Medical Research in Norway. Of the >120,000 participants in the HUNT 1-3<br>study, 69,635 individuals of European ancestry have been genotyped using Illumina Human<br>CoreExome v1.1 array with 70,000 additional cus Committee for Medical Research in North II, 2013 and 2013 parallysing Illumina Human CoreExome v1.1 array with 70,000 additional custom content beads and imputed to 25M genetic markers using 2,202 whole-genome sequenced sa study, 19,719,538 individuals of European ancestry, interacting study, per casing including the studies.<br>CoreExome v1.1 array with 70,000 additional custom content beads and imputed to 25M<br>genetic markers using 2,202 whole genetic markers using 2,202 whole-genome sequenced samples from HUNT together wit<br>Haplotype Reference Consortium reference panel<sup>37,38</sup>. We used a combination of hospita<br>outpatient, and emergency room discharge diagnoses ( Haplotype Reference Consortium reference panel<sup>37,38</sup>. We used a combination of hospital,<br>outpatient, and emergency room discharge diagnoses (ICD-9 and ICD-10) along with self-<br>reported variables and lab measurements to id Haplotype Reference Consortium reference panel<sup>37,39</sup>. We used a combination of hospital,<br>outpatient, and emergency room discharge diagnoses (ICD-9 and ICD-10) along with self-<br>reported variables and lab measurements to id infarction (MI) or diabetes for as many samples as possible. The age of participation in HUNT  $1$ reported variables and the measurements to identify pasts and structure in structure measurements (Supplementary Table 6,7). Self-reported family history of disease was obtained from survey<br>questionnaires from HUNT 1-3 (Su (Supprementary Table 8). Variables across HUNT collections<br>were collapsed to create a single indicator variable for first-degree family history of myocardi<br>infarction (MI) or diabetes for as many samples as possible. The a were collapsed to create a single indicator variable for first-degree family history of myocard<br>infarction (MI) or diabetes for as many samples as possible. The age of participation in HUNT<br>3 was recorded with the earliest were compressed to create a single indicator variable for minimizing angly during the indication in HUNT 1-3 was recorded with the earliest age being taken if the participant answered the question in multiple collections.<br> infarction (MI) or diabeted with the earliest age being taken if the participant answered the question in multiple collections.<br>Intervalse and the participant answered the question in multiple collections.<br>The UK Biobank i

### UK Biobank

3 was recorded with the collections.<br>3 was reliest age being with the UK Biobank<br>3 The UK Biobank is a population-based cohort collected from multiple sites across the<br>3 United Kingdom<sup>39,40</sup>. Genotyped and imputed data fo Multiple collections<br>The UK Bioba<br>United Kingdom<sup>39,40</sup>.<br>ancestry were used f  $Xingdom<sup>39,40</sup>$ . Genotyped and imputed data for  $408,577$  individuals of white British y were used for this analysis. Case and control status was ascertained using phecodes  $x$ United Kingdom<sup>39,40</sup>. Genotyped and imputed data for 408,577 individuals of white British<br>ancestry were used for this analysis. Case and control status was ascertained using phecoc<br>ancestry were used for this analysis. Ca ancestry were used for this analysis. Case and control status was ascertained using phecodes<sup>41</sup>.<br>25<br>25 Family history of heart disease or<br>and collapsed into a single indicator variable for first degree family history of heart disease or<br>diabetes (Supplementary Table 6-8).<br>**Polygenic scores**<br>We used previously generated weig

### Polygenic scores

and collapsed in the single mentary Table 6-8).<br> **Polygenic scores**<br>
We used previously generated weights for an optimized set of genome-wide variants<br>
(6.6M for CAD and 6.9M for T2D) to calculate the disease-specific PGS<sup></sup> Polygenic scores<br>We used previously generated<br>(6.6M for CAD and 6.9M for T2D) to c<br>weights<sup>6</sup> were based on genetic effec or CAD and 6.9M for T2D) to calculate the disease-specific PGS<sup>10</sup>. Briefly, these<br><sup>6</sup> were based on genetic effect estimates (beta) from large GWAS for CAD (N=60,801<br>nd 123,504 controls) and T2D (N=26,676 cases and 132,53 (6.6M for CAD and 6.9M for T2D) to calculate the disease-specific PGS<sup>40</sup>. Briefly, these<br>weights<sup>6</sup> were based on genetic effect estimates (beta) from large GWAS for CAD (N=6<br>cases and 123,504 controls) and T2D (N=26,676 weights"<br>cases and<br>variants<br>weights 1<br>participa<br>the LDpr  $\alpha$  123,504 controls) and T2D (N=26,676 cases and 132,532 controls) and genetic<br>were pruned using LDpred and tuning parameters of 0.001 and 0.01 respectively. The<br>for CAD and T2D were applied to individual-level imputed variants were pruned using LDpred and tuning parameters of 0.001 and 0.01 respectively<br>weights for CAD and T2D were applied to individual-level imputed dosages for each HUI<br>participant and UKB participant to estimate PGS<sub></sub> weights for CAD and T2D were applied to individual-level imputed dosages for each HUNT<br>participant and UKB participant to estimate  $PGS_{CAD}$  and  $PGS_{T2D}$ . A limitation of this analysis is<br>the LDpred tuning parameters were o participant and UKB participant to estimate PGS<sub>CAD</sub> and PGS<sub>T2D</sub>. A limitation of this analys<br>the LDpred tuning parameters were optimized in UKB phase 1, but the weights came from<br>external GWAS and the performance did not participant and UKB participant of EC<sub>RC</sub> and PGS<sub>T2D</sub> . And PGS<sub>T2D</sub> . And PGST<sub>2D</sub> . And PGST<sub>2D</sub> . This analysis<br>the LDpred tuning parameters were optimized in UKB phase 1, but the weights came from<br>external GWAS and th the LDP setternal GWAS and the performance did not vary widely across the models in the optimizate<br>step.<br>Statistical analysis<br>We estimated the odds ratios (ORs) for models with PGS and self-reported family

### Statistical analysis

external GMAS and the performance did not vary places in the case in the performance<br>step.<br>Statistical analysis<br>We estimated the odds ratios (ORs) for models with PGS and self-reported family<br>history as predictors using lo step<br><mark>Stati:</mark><br>histor<br>covar as predictors using logistic regression with binomial link function adjusting for<br>tes including the effect of sex, age at biobank enrollment, age at biobank enrollme<br>d, birth year, and first four genetic principal componen reprending the effect of sex, age at biobank enrollment, age at biobank enrol<br>squared, birth year, and first four genetic principal components. In analyses where we<br>the odds ratio for predictors, we perform several variabl squared, birth year, and first four genetic principal components. In analyses where we estimathe odds ratio for predictors, we perform several variable transformations. Birth year is transformed to the age in 2021 so the o shipped, birth year, and first four details and first form and first four generations. Birth year, is transformed to the age in 2021 so the odds ratio is on the scale of risk rather than protection<br>transformed to the age i transformed to the age in 2021 so the odds ratio is on the scale of risk rather than prote-<br>transformed to the age in 2021 so the odds ratio is on the scale of risk rather than prote $t$  transformed to the age in 2021 so the odds rather than  $\alpha$  rather than protection is on the scale of risk rather than  $\alpha$ 

(i.e or in alized (using R package RNOMni) and age-related covariates are scaled to have a r<br>o and variance of 1. When evaluating model selection for family history and PGS we use<br>standard multivariable logistic regression o and variance of 1. When evaluating model selection for family history and PGS we used<br>standard multivariable logistic regression. When considering risk thresholds using family<br>history and PGS, we used an indicator variab of the numerology of the transition for the 1. When evaluating model in the selection standard multivariable logistic regression. When considering risk thresholds using family history and PGS, we used an indicator variable standard multion of Set an indicator variable based on a percentile threshold for PGS w<br>without conditioning on family history. Reported p-values from logistic regression are fro<br>Wald tests, and the p-values from model com menty and PGS, we use annualized Panameter and the percentile interaction of a matrix<br>without conditioning on family history. Reported p-values from logistic regression are from<br>Wald tests, and the p-values from model comp wald tests, and the p-values from model comparison with ANOVA are Likelihood Ratio Test<br>Statistical analyses were conducted using R version 4.0.3 software. Hereafter, when describ<br>the predictors, family history refers to s Statistical analyses were conducted using R version 4.0.3 software. Hereafter, when describing<br>the predictors, family history refers to self-reported family history from surveys<br>. Statistical analyses were conducted using R version 4.0.3 socialized using the predictors, family history refers to self-reported family history from surveys the predictors, family history refers to self-reported family history from surveys

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.06.25.21259158;](https://doi.org/10.1101/2021.06.25.21259158) this version posted June 28, 2021. The copyright holder for this preprint

References<br>1. Lloyd-Jones, D. M. et al. Parental Cardiovascular Disease as a Risk Factor for

- 1. Lloyd-Jones, D. M. et al. Parental Cardiovascular Disease as a Risk Pactor for<br>Cardiovascular Disease in Middle-aged Adults: A Prospective Study of Parent<br>Offspring. JAMA 291, 2204 (2004).<br>2. Scott, R. et al. The link b Coffspring. JAMA 291, 2204 (2004).<br>Scott, R. *et al.* The link between Family History and risk of Type 2 Diabetes is Not E<br>by Anthropometric, Lifestyle or Genetic Risk Factors: the EPIC-InterAct Study.<br>Diabetologia 56, 60– Offspring. JAMA 291, 2204 (2004).<br>Scott, R. *et al.* The link between Far<br>by Anthropometric, Lifestyle or Ge<br>*Diabetologia* 56, 60–69 (2013).<br>Falconer, D. S. The inheritance of li<br>among relatives. *Ann. Hum. Genet.* 2. Scott, K. et al. The link between Family History and risk of Type 2 Diabetes is Not Explained<br>by Anthropometric, Lifestyle or Genetic Risk Factors: the EPIC-InterAct Study.<br>Diabetologia 56, 60–69 (2013).<br>3. Falconer, D.
- Diabetologia 56, 6o–69 (2013).<br>Falconer, D. S. The inheritance of liability to certain diseases, estimated from the<br>among relatives. Ann. Hum. Genet. 29, 51–76 (1965).<br>Falconer, D. S. The inheritance of liability to diseas *Blabetologia* 50, 00–09 (2013).<br>Falconer, D. S. The inheritance<br>among relatives. *Ann. Hum. Ge*<br>Falconer, D. S. The inheritance<br>particular reference to diabete<br>Cornelis. M. C., Zaitlen. N., Hu.
- 3. Falconer, D. S. The inheritance of liability to diseases with variable age of onset, with<br>4. Falconer, D. S. The inheritance of liability to diseases with variable age of onset, with<br>6. particular reference to diabetes among relatives. Ann. Hom. Genet. 29, 51–70 (1905).<br>Falconer, D. S. The inheritance of liability to diseases<br>particular reference to diabetes mellitus. Ann. Hum. (<br>Cornelis, M. C., Zaitlen, N., Hu, F. B., Kraft, P. & Price
- 
- particular reference to diabetes mellitus. Ann. Hum. Genet. 31, 1–20 (1967).<br>
5. Cornelis, M. C., Zaitlen, N., Hu, F. B., Kraft, P. & Price, A. L. Genetic and environment.<br>
components of family history in type 2 diabetes. particular reference to diabetes mellitus. Ann. Hum. Genet. 31, 1–20 (1907).<br>Cornelis, M. C., Zaitlen, N., Hu, F. B., Kraft, P. & Price, A. L. Genetic and env<br>components of family history in type 2 diabetes. Hum. Genet. 13 5. Components of family history in type 2 diabetes. Hum. Genet. 134, 259–267 (2015).<br>
6. Lu, Y. et al. Genetic risk scores and family history as predictors of schizophrenia in Nord<br>
registers. *Psychol. Med.* 48, 1201–1208 components of family filstory in type 2 diabetes. *Hum. Genet.* 134, 259–207 (2015).<br>Lu, Y. *et al. Genetic risk scores and family history as predictors of schizophrenia in M<br>registers. <i>Psychol. Med. 48, 1201–1208 (2018).*
- 6. Lo, T. et al. Genetic risk scores and family history as predictors of schizophrenia in Nordic<br>registers. *Psychol. Med. 48, 1201–1208 (2018).*<br>7. Ripatti, S. *et al. A multilocus genetic risk score for coronary heart di*
- registers. *Psychol. Med. 4*0, 1201–1200 (2010).<br>Ripatti, S. *et al.* A multilocus genetic risk score<br>prospective cohort analyses. *The Lancet* 376, 1<br>Tikkanen Emmi, Havulinna Aki S., Palotie Aarn<br>Genetic Risk Prediction a prospective cohort analyses. *The Lancet* 376, 1393–1400 (2010).<br>
8. Tikkanen Emmi, Havulinna Aki S., Palotie Aarno, Salomaa Veikko, & Ripatti Samuli.<br>
Genetic Risk Prediction and a 2-Stage Risk Screening Strategy for Coro prospective cohort analyses. The Lancet 370, 1393–1400 (2010).<br>Tikkanen Emmi, Havulinna Aki S., Palotie Aarno, Salomaa Veikk<br>Genetic Risk Prediction and a 2-Stage Risk Screening Strategy fo<br>Arterioscler. Thromb. Vasc. Biol Senetic Risk Prediction and a 2-Stage Risk Screening Strategy for Coronary Heart Di<br>A*rterioscler. Thromb. Vasc. Biol.* 33, 2261–2266 (2013).<br>9. Abraham, G. *et al.* Genomic prediction of coronary heart disease. *Eur. Hear*
- Arterioscler. Thromb. Vasc. Biol. 33, 2261–2266 (2013).<br>Abraham, G. et al. Genomic prediction of coronary heart disease. *Eur. Heart J.* 37, 3267–<br>3278 (2016). Arterioscler. Thromb. Vasc. Biol. 33, 2201–2200 (2013).<br>Abraham, G. *et al*. Genomic prediction of coronary hea<br>3278 (2016). 9. Abraham, G. et al. Genomic prediction of coronary heart disease. *Eur. Heart J.*  $37, 3207$ –<br>3278 (2016). 3278 (2016).
- 
- 10. Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals<br>11. Mars, N. et al. Polygenic and clinical risk scores and their impact on age at onset and<br>11. Mars, N. et al. Polygenic and cl Mars, N. et al. Polygenic and clinical risk scores and their impact on age at<br>prediction of cardiometabolic diseases and common cancers. *Nat. Med.* 1–<br>doi:10.1038/s41591-020-0800-0.<br>Ruderfer, D. M., Korn, J. & Purcell, S. 11. Mars, N. et al. Polygenic and clinical risk scores and their impact on age at onset and<br>prediction of cardiometabolic diseases and common cancers. *Nat. Med.* 1–9 (2020)<br>doi:10.1038/541591-020-0800-0.<br>12. Ruderfer, D.
- prediction of cardiometabolic diseases and common cancers. Nat. Med. 1–9 (2020)<br>doi:10.1038/s41591-020-0800-0.<br>Ruderfer, D. M., Korn, J. & Purcell, S. M. Family-based genetic risk prediction of<br>multifactorial disease. *Gen* Ruderfer, D. M., Korn, J. & Purce<br>multifactorial disease. *Genome M*<br>Do, C. B., Hinds, D. A., Francke, l<br>for Predicting Risk of Complex D<br>Chatteriee. N. *et al*. Proiecting th
- multifactorial disease. *Genome Med.* 2, 2 (2010).<br>13. Do, C. B., Hinds, D. A., Francke, U. & Eriksson, N. Comparison of Family History.<br>14. Chatterjee, N. *et al.* Projecting the performance of risk prediction based on po monnactorial disease. Genome Med. 2, 2 (2010).<br>Do, C. B., Hinds, D. A., Francke, U. & Eriksson, N<br>for Predicting Risk of Complex Disease. *PLoS Ge*<br>Chatterjee, N. *et al.* Projecting the performance<br>analyses of genome-wide
- 13. Do, C. B., Hinds, D. B., Hinds, D. B. B., Hinds, D. B., Hinds, N. 2012).<br>14. Chatterjee, N. *et al.* Projecting the performance of risk prediction based on polygenic<br>14. Chatterjee, N. *et al.* Projecting the performan for Predicting Risk of Complex Disease. PLoS Genet. 0, (2012).<br>Chatterjee, N. *et al.* Projecting the performance of risk predicti<br>analyses of genome-wide association studies. *Nat. Genet.* 45, 4<br>Mars, N. *et al.* The role
- 14. Chatterjee, N. et al. 1 Tojecting the performance of risk prediction based on polygenic<br>analyses of genome-wide association studies. *Nat. Genet.* 45, 400-405e3 (2013).<br>15. Mars, N. *et al.* The role of polygenic risk
- analyses of genome-wide association stodies. *Nat. Genet.* 45, 400-405e3 (2013).<br>Mars, N. *et al.* The role of polygenic risk and susceptibility genes in breast cancer<br>course of life. *Nat. Commun*. **11,** 6383 (2020).<br>So, 15. Mars, N. et al. The role of polygenic risk and sosceptibility genes in breast cancer over the<br>course of life. *Nat. Commun.* 11, 6383 (2020).<br>16. So, H.-C., Kwan, J. S. H., Cherny, S. S. & Sham, P. C. Risk Prediction o course of life. Mat. Common. 11, 0303 (2020).<br>So, H.-C., Kwan, J. S. H., Cherny, S. S. & Shan<br>from Family History and Known Susceptibility<br>Screening. *Am. J. Hum. Genet.* **88**, 548–565 (2<br>Chen, H. *et al.* Adding Genetic R
- 16. So, H. C., H.-C., H.-C., H.-C., H.-C., H.-C., H.-C., With Applications for Cancer<br>16. Screening. *Am. J. Hum. Genet.* **88**, 548–565 (2011).<br>17. Chen, H. *et al.* Adding Genetic Risk Score to Family History Identifies Screening. *Am. J. Hum. Genet.* **88,** 548–565 (2011).<br>Chen, H. *et al.* Adding Genetic Risk Score to Family History Identifies Twice as Marisk Men for Prostate Cancer: Results from The Prostate Cancer Prevention Trial.<br>Pro Screening. Am. J. Hum. Genet. **80,** 540–505 (2011).<br>Chen, H. *et al*. Adding Genetic Risk Score to Family<br>risk Men for Prostate Cancer: Results from The Pro<br>*Prostate* **76**, 1120–1129 (2016).<br>Wolford, B. Improved predictio 17. Chen, H. et al. Adding Genetic Risk Score to Family History Identifies Twice as Many High-<br>risk Men for Prostate Cancer: Results from The Prostate Cancer Prevention Trial. The<br>Prostate 76, 1120–1129 (2016).<br>18. Wolford
- risk Men for Prostate Cancer: Resolts from The Prostate Cancer Prevention Trial. *The*<br>Prostate **76**, 1120–1129 (2016).<br>Wolford, B. Improved prediction of common complex diseases using family history<br>informed genetic risk Prostate 76, 1120–1129 (2010).<br>Wolford, B. Improved prediction<br>informed genetic risk scores. in  $\begin{pmatrix} 1 & 1 & 1 \ 1 & 1 & 1 \end{pmatrix}$ <br>informed genetic risk scores. in (2019). informed genetic risk scores. in (2019).
- disease improves polygenic risk scores in diverse populations. *bioRxiv* 2021.04.15.439<br>(2021) doi:10.1101/2021.04.15.439975.<br>20. Inouye, M. *et al.* Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adul<br>Impli
- (2021) doi:10.1101/2021.04.15.439975.<br>(2021) doi:10.1101/2021.04.15.439975.<br>Inouye, M. *et al.* Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults:<br>Implications for Primary Prevention. *J. Am. Coll. Cardi*
- (2022) dones (20221-2021-41239373)<br>Inouye, M. *et al.* Genomic Risk Predicti<br>Implications for Primary Prevention. *J.*<br>Selmer, R. *et al.* NORRISK 2: A Norweg<br>myocardial infarction. *Eur. J. Prev. Carc*<br>Hippislev-Cox. J., 20. Inouye, M. et al. Genomic Risk Prediction of Coronary Artery Disease in 400,000 Adults.<br>
21. Selmer, R. *et al.* NORRISK 2: A Norwegian risk model for acute cerebral stroke and<br>
21. Selmer, R. *et al.* NORRISK 2: A Nor
- Implications for Primary Prevention. J. Am. Coll. Cardiol. **72,** 1883–1893 (2018).<br>Selmer, R. *et al.* NORRISK 2: A Norwegian risk model for acute cerebral stroke<br>myocardial infarction. *Eur. J. Prev. Cardiol.* **24,** 773–7 21. Jenner, R. et al. NORRISK 2. A Norwegian risk model for acute cerebral stroke and<br>myocardial infarction. *Eur. J. Prev. Cardiol.* **24,** 773–782 (2017).<br>22. Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and myocardial infarction. *Eur. J. Prev.* Cardiol. **24,** 773–792 (2017).<br>Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and<br>prediction algorithms to estimate future risk of cardiovascular<br>study. *BMJ* 357, j2099 (2 22. Hippiscap. J., J., Corpland, T. Development and validation of 20.000 prediction algorithms to estimate future risk of cardiovascular disease: prospective coho<br>23. Grundy, S. M. et al. 2018<br>AHA/ACC/AACVPR/AAPA/ABC/ACPM/
- 

prediction algorithms to estimate in the condett<br>Frundy, S. M. *et al.* 2018<br>AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the<br>Management of Blood Cholesterol: Executive Summary: A Report of the Amer study. *BMJ* 357, J2099 (2017).<br>Grundy, S. M. *et al*. 2018<br>AHA/ACC/AACVPR/AAPA/AB<br>Management of Blood Choles<br>of Cardiology/American Hear<br>Am. Coll. Cardiol. 73. 3168–32 23. Grundy, S. M. et al. 2016<br>AHA/ACC/AACVPR/AAP,<br>Management of Blood Cl<br>of Cardiology/American I<br>Am. Coll. Cardiol. 73, 3168<br>24. Llovd-Jones. D. M. et al. I Management of Blood Cholesterol: Executive Summary: A Report of the American College<br>of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J.<br>Am. Coll. Cardiol. 73, 3168–3209 (2019).<br>Lloyd-Jo Management of Blood Christian Entertainment of Blood Cholesterolinian Cholesterol:<br>1997 - Management of Cardiol. 73, 3168–3209 (2019).<br>1998 - Lloyd-Jones, D. M. et al. Framingham risk score and prediction of lifetime risk

- of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J.<br>Am. Coll. Cardiol. 73, 3168–3209 (2019).<br>Lloyd-Jones, D. M. et al. Framingham risk score and prediction of lifetime risk for corona<br>he
- Am. Coll. Caralol. 73, 3166–3209 (2019).<br>Lloyd-Jones, D. M. *et al.* Framingham ris<br>heart disease. *Am. J. Cardiol.* 94, 20–24<br>SCORE2 working group and ESC Cardio<br>algorithms: new models to estimate 10-<br>Heart J. (2021) doi: 24. Lloyd-Jones, D. M. et al. Framingham risk score and prediction of lifetime risk for coronary<br>
25. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction<br>
25. SCORE2 working group and ES heart disease. Am. J. Cardiol. 94, 20–24 (2004).<br>SCORE2 working group and ESC Cardiovascula<br>algorithms: new models to estimate 10-year ris<br>Heart J. (2021) doi:10.1093/eurheartj/ehab309.<br>Goff David C. *et al.* 2013 ACC/AHA 25. Scottimulary and Estimate 10-year risk of cardiovascular disease in Europe. Eur.<br>
25. Score Heart J. (2021) doi:10.1093/eurheartj/ehab309.<br>
26. Goff David C. *et al.* 2013 ACC/AHA Guideline on the Assessment of Cardiov
- algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur.*<br>Heart J. (2021) doi:10.1093/eurheartj/ehab309.<br>Goff David C. *et al.* 2013 ACC/AHA Guideline on the Assessment of Cardiovascular R Heart J. (2021) doi:10.1093/eurheartj/ehab309.<br>Goff David C. *et al.* 2013 ACC/AHA Guideline or<br>Circulation **129,** S49–S73 (2014). 26. Goff David C. et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.<br>Circulation 129, 549–573 (2014). Circulation 129, S49–S73 (2014).
- 27. Janssens, A. C. J. W. et al. Accoracy of sen-reported rannity history is strongly influenced by<br>the accuracy of self-reported personal health status of relatives. J. Clin. Epidemiol. 65, 82–<br>89 (2012).<br>28. Versmissen,
- 
- the accoracy of sen-reported personal health status of relatives. J. Clin. Epidemiol. 05, 02–<br>89 (2012).<br>Versmissen, J. et al. Efficacy of statins in familial hypercholesterolaemia: a long term<br>cohort study. *BMJ* 337, a24 erg<br>Cersmisse<br>Cohort stum<br>Salami, J. J.<br>Population<br>Cardiol. 2. 28. Versmissen, J. et al. Emcacy of statins in familiar hypercholesterolaemia: a long term<br>cohort study. *BMJ* 337, a2423 (2008).<br>29. Salami, J. A. *et al*. National Trends in Statin Use and Expenditures in the US Adult<br>Po cohort study. *BMJ* 337, a2423 (2000).<br>Salami, J. A. *et al.* National Trends in '<br>Population From 2002 to 2013: Insigh<br>*Cardiol*. **2,** 56–65 (2017).<br>Pencina, M. J. *et al*. The Expected 30-'<br>Prevention of Cardiovascular D 29. Salami, J. A. et al. National Trends in Statin Ose and Expenditures in the OS Adult<br>Population From 2002 to 2013: Insights From the Medical Expenditure Panel Surve<br>Cardiol. 2, 56–65 (2017).<br>30. Pencina, M. J. et al. Th
- raponation From 2002 to 2013: Insights From the Medical Expenditore Panel Solvey. JAMA<br>Cardiol. 2, 56–65 (2017).<br>Pencina, M. J. et al. The Expected 30-Year Benefits of Early Versus Delayed Primary<br>Prevention of Cardiovascu Cardiol. 2, 50–05 (2017).<br>Pencina, M. J. *et al.* The<br>Prevention of Cardiovas<br>Martin, A. R. *et al.* Clinic.<br>disparities. *Nat. Genet. 5*<br>Martin. A. R. *et al.* Huma
- 30. Pencina, M. J. et al. The Expected 30-Year Benefits of Early Versus Delayed Pilmary<br>Prevention of Cardiovascular Disease by Lipid Lowering. *Circulation* 142, 827–837 (20<br>31. Martin, A. R. *et al.* Clinical use of curr Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health<br>disparities. *Nat. Genet.* 51, 584 (2019).<br>Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction across<br>
- 31. Martin, A. R. et al. Clinical use of corrent polygenic risk scores may exacerbate health<br>disparities. Nat. Genet. 51, 584 (2019).<br>32. Martin, A. R. et al. Human Demographic History Impacts Genetic Risk Prediction acro<br>
- disparities. Nat. Oerlet. 51, 504 (2019).<br>Martin, A. R. *et al.* Human Demograph<br>Diverse Populations. *Am. J. Hum. Gene*<br>Sohail, M. *et al.* Polygenic adaptation c<br>stratification in genome-wide associati<br>Wei. J. *et al.* C 32. Martin, A. R. et al. Homan Demographic History Impacts Genetic Risk Prediction across<br>Diverse Populations. A*m. J. Hum. Genet.* **100**, 635–649 (2017).<br>33. Sohail, M. *et al.* Polygenic adaptation on height is overestim
- Biverse Populations. Am. J. Hum. Genet. 100, 035–049 (2017).<br>Sohail, M. et al. Polygenic adaptation on height is overestimat<br>stratification in genome-wide association studies. *eLife* **8**, e39;<br>Wei, J. *et al*. Calibration 33. Sohan, M. et al. Polygenic adaptation on height is overestimated due to uncorrected<br>stratification in genome-wide association studies. *eLife* **8**, e39702 (2019).<br>34. Wei, J. *et al.* Calibration of polygenic risk scor stratification in genome-wide association stodies. *eLife o, e39702* (2019).<br>Wei, J. *et al.* Calibration of polygenic risk scores is required prior to clinica<br>results of three common cancers in UKB. *J. Med. Genet.* (20 34. Wei, 3. et al. Calibration of polygenic risk scores is required prior to clinical implementation.<br>
results of three common cancers in UKB. *J. Med. Genet.* (2020) doi:10.1136/jmedgenet-<br>
2020-107286.<br>
35. Sinnott-Armst
- results of three common cancers in OKB. J. Med. Genet. (2020) doi:10.1130/jmedgenet-<br>2020-107286.<br>Sinnott-Armstrong, N. *et al*. Genetics of 35 blood and urine biomarkers in the UK Bioba<br>*Nat. Genet.* 53, 185–194 (2021). 2020-2020<br>Sinnott-Armst<br>*Nat. Genet.* 53 35. Sinnott-Armstrong, N. et al. Genetics of 35 blood and ome biomarkers in the UK Biobank.<br>Nat. Genet. 53, 185–194 (2021).  $N$ ut. Genet. 53, 105–194 (2021).
- 
- 36. Krokstad, 3. et al. Cohort Profile: the HUNT Stody, Norway. *Int. J. Epidemiol.* 42, 900–977<br>37. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat.*<br>38. Zhou, W. *et al.* Impro ,<br>McCart<br>*Genet.*<br>Zhou, V<br>genoty<br>Bvcroft
- 37. McCarthy, 3. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat.<br>
38. Zhou, W. et al. Improving power of association tests using multiple sets of imputed<br>
38. Zhou, W. et al. Improving power of Benet. **40,** 1279–1203 (2010).<br>Zhou, W. *et al.* Improving pov<br>genotypes from distributed re<br>Bycroft, C. *et al.* The UK Biob.<br>Mature 562, 203–209 (2018).<br>Sudlow. C. *et al*. UK Biobank:
- 38. Zhou, w. et al. Improving power or association tests using multiple sets of imputed<br>genotypes from distributed reference panels. *Genet. Epidemiol.* 41, 744–755 (2017).<br>39. Bycroft, C. et al. The UK Biobank resource wi
- genotypes from distributed reference panels. O*enet. Epidemiol.* 41, 744–755 (2017).<br>Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic dat<br>Nature 562, 203–209 (2018).<br>Sudlow, C. *et al.* UK Bio 39. Bycroft, C. et al. The OK Biobank resource with deep phenotyping and genomic data.<br>
Ao. Sudlow, C. et al. UK Biobank: An Open Access Resource for Identifying the Causes of a<br>
Wide Range of Complex Diseases of Middle an
- Nature 502, 203–209 (2010).<br>Sudlow, C. *et al*. UK Biobank<br>Wide Range of Complex Dise<br>Wei, W.-Q. *et al*. Evaluating <sub>I</sub><br>for phenome-wide associatic<br>e0175508 (2017). 40. Sociow, C. et al. UK Biobank: An Open Access Resource for Identifying the Causes of a<br>Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* 12, e1001779 (201<br>41. Wei, W.-Q. *et al.* Evaluating phecodes, cli Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. 12, e1001/79 (2015).<br>Wei, W.-Q. *et al.* Evaluating phecodes, clinical classification software, and ICD-9-CM code:<br>for phenome-wide association studies in the 41. Wei, W.-Q. et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes<br>for phenome-wide association studies in the electronic health record. *PLOS ONE* 12,<br>e0175508 (2017). for phenome-wide association studies in the electronic health record. PLOS ONE 12,<br>e0175508 (2017).  $e^{-2}$